Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is BioSpecifics Technologies Corp. (BSTC) A Good Stock To Buy Right Now?

Page 1 of 2

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review of these public filings is finally over, so this article is set to reveal the smart money sentiment towards BioSpecifics Technologies Corp. (NASDAQ:BSTC).

BioSpecifics Technologies Corp. (NASDAQ:BSTC) shares didn’t see a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 6 hedge funds’ portfolios at the end of the third quarter of 2016. At the end of this article we will also compare BSTC to other stocks including Compugen Ltd. (USA) (NASDAQ:CGEN), American Public Education, Inc. (NASDAQ:APEI), and Trinity Biotech plc (ADR) (NASDAQ:TRIB) to get a better sense of its popularity.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

lab, scientist, tech, chemistry, test, experiment, reaction, pharmaceutical, medical, liquid, fluid, dropper, tool, pharmacology, sample, organic, pipette, drug, chemist, bio

SUWIT NGAOKAEW/Shutterstock.com

Now, we’re going to review the new action surrounding BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Hedge fund activity in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

At Q3’s end, a total of 6 of the hedge funds tracked by Insider Monkey were bullish on this stock, unchanged from the previous quarter. By comparison, 8 hedge funds held shares or bullish call options in BSTC heading into this year. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were increasing their holdings considerably (or already accumulated large positions).

HedgeFundSentimentChart

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Renaissance Technologies, one of the largest hedge funds in the world, holds the largest position in BioSpecifics Technologies Corp. (NASDAQ:BSTC). According to regulatory filings, the fund has a $13.8 million position in the stock. Sitting at the No. 2 spot is Chuck Royce of Royce & Associates, with a $3.5 million position. Remaining hedge funds and institutional investors that are bullish consist of Cliff Asness’ AQR Capital Management, Nathan Fischel’s DAFNA Capital Management and John Overdeck and David Siegel’s Two Sigma Advisors. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2